Inseego (NASDAQ:INSG) Bolsa

Inseego

Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).

Inseego Corp

EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.32 by 25 percent. This is a 700 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $166.63 million which beat the analyst consensus estimate of $158.08 million by 5.41 percent. This is a 82.98 percent increase over sales of $91.06 million the same period last year.

Earnings

Earnings Beats

News

EVER

UPDATE: EverQuote Q1 Adj. EPS $0.40 Beats $0.32 Estimate, Sales $166.63M Beat $158.08M Estimate

Datadog Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) announced Monday that it has acquired<a target="_blank" href="v" rel="noreferrer noopener"> Eppo</a>, a platform specializing in feature flagging and experimentation. The company will use the acquisition to enhance its Product Analytics suite and streamline the development process for its customers. Deal terms were not disclosed.
The acquisition is designed to help developers, product managers, and analysts unify their tools and provide clearer insights into how new features and code changes affect business outcomes.
By integrating Eppo, Datadog plans to offer a comprehensive product analytics solution, replacing the fragmented workflows many teams face.
Also Read: <a href="https://www.benzinga.com/news/25/05/45193411/mcdonalds-to-rally-more-than-10-here-are-10-top-analyst-forecasts-for-monday" target="_blank" rel="noreferrer noopener">McDonald&#8217;s To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Monday</a>
This move enables Datadog to deliver a unified platform that allows teams to manage feature flags, run experiments, and monitor key metrics, ultimately simplifying product impact analysis as AI adoption continues to grow.
Michael Whetten, Datadog&#8217;s vice president of product, noted that as companies deploy more AI models, measuring their impact becomes increasingly complex.
He explained that experimentation helps solve this challenge by enabling teams to compare models, assess user engagement, and evaluate cost tradeoffs, leading to more effective AI products. The combined tools aim to make development workflows faster and more reliable.
Eppo will continue to support its current customer base while expanding under the Eppo by Datadog brand. The acquisition further positions Datadog to address the increasing complexity of today&#8217;s software and AI landscapes.
Datadog held cash and equivalents of <a href="https://www.benzinga.com/news/earnings/25/02/43694460/datadog-q4-earnings-margins-shrink-outlook-lags-expectations" target="_blank" rel="noreferrer noopener">$4.2 billion</a> as of December 31, 2024.
<h2 class="wp-block-heading">Datadog Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Datadog have an average 1-year price target of $146.9, representing an expected upside of 38.98%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Datadog, while 17 analysts have bullish ratings. The street high price target from Macquarie is $200.0, while the street low from Morgan Stanley is $115.0.
Price Action: DDOG shares closed higher by 0.67% to $105.70 on Monday.
Photo via Shutterstock

Tech

DDOG

Datadog Acquires Eppo To Boost Product Analytics And Simplify AI Workflows

WIIM

WeRide shares are trading higher after the company announced it expanded its strategic partnership with Uber to bring autonomous vehicles to 15 additional cities.

Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.32 by 87.5 percent. This is a 85.19 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $59.25 million which missed the analyst consensus estimate of $117.32 million by 49.50 percent. This is a 43.83 percent decrease over sales of $105.49 million the same period last year.

Earnings Misses

Black Stone Minerals Q1 EPS $0.04 Misses $0.32 Estimate, Sales $59.25M Miss $117.32M Estimate

Banco Latinoamericano (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLX#NYSE">BLX</a>) reported quarterly earnings of $1.40 per share. This is unchanged from the same period last year. The company reported $77.90 million in sales this quarter. This is a 7.30 percent increase over sales of $72.60 million the same period last year.

Banco Latinoamericano Q1 EPS $1.40, Same YoY, Sales $77.90M Up From $72.60M YoY

TD Bank Group ("TD" or the "Bank") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TD#NYSE">TD</a>) announced today that it expects catastrophe claims of approximately $50 million after reinsurance and before tax to be reflected in the Bank's Wealth Management &amp; Insurance segment's second-quarter results.&nbsp;

TSX:TD

TD Bank Expects Catastrophe Claims Of ~$50M After Reinsurance And Before Tax To Be Reflected In The Bank's Wealth Management & Insurance Segment's Second-quarter Results.

BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $126.87 million</a>.
The increase was primarily due to $134.2 million (+$45.3 million yoy) in Orladeyo&#8217;s net revenue in the first quarter of 2025, compared to $88.9 million in the first quarter of 2024 (+51.0 percent yoy).&nbsp;
Orladeyo&#8217;s net revenue increased to $134.24 million&nbsp;from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190350/biocryst-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">$88.87 million a year ago</a>.
Net income for the first quarter of 2025 was $32 thousand, or $0.00 per share, compared to a net loss of $35.4 million, or $0.17 per share, for the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">first quarter of 2024</a>.&nbsp;
Operating income for the first quarter of 2025 was $21.2 million, compared to an operating loss of $14.5 million for the first quarter of 2024. Non-GAAP operating income, excluding stock-based compensation expense, was $42.6 million for the first quarter of 2025, compared to a non-GAAP operating loss of $0.8 million for the first quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45193720/immunitybio-slapped-with-fda-refusal-to-file-letter-for-expanded-use-of-its-bladder-cancer-drug" rel="noreferrer noopener">ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug</a>
Guidance: BioCryst increased its 2025 outlook for Orladeyo revenue to $580 million and $600 million <a target="_blank" href="https://www.benzinga.com/25/02/43918295/biocryst-pharmaceuticals-reveals-interim-data-from-orladeyo-pediatric-trial-reports-mixed-q4-earnings" rel="noreferrer noopener">from $535 million and $550 million</a>.
The company now expects full year 2025 operating expenses will be $440 million to $450 million (previously $425 million to $435 million).
The company is accelerating its expectation for sustainable profitability and positive cash flows by a year.
The company now expects to deliver net income and positive cash flows for the full year 2025 (previously, both were expected for the full year 2026).
Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash, and investments from year-end 2024 to year-end 2025, not including the impact of the $75 million Pharmakon prepayment made in April 2025.
Price Action:&nbsp;BCRX stock closed higher by 23.50% to $11.03&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45196561/loews-posts-mixed-q1-results-pipeline-strength-offsets-insurance-and-hotel-weakness" target="_blank" rel="noreferrer noopener">Loews Posts Mixed Q1 Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>

Biotech

Guidance

Health Care

Movers

Trading Ideas

General

BCRX

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

Franklin Resources Reports Preliminary Month-End AUM Of $1.53T At April 30, 2025, Compared To $1.54T At March 31, 2025

Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) reported financial results for the first quarter after the market close on Monday. Shares are moving lower after the company paused guidance. Here&#8217;s what you <a href="https://www.benzinga.com/pressreleases/25/05/b45206394/mattel-reports-first-quarter-2025-financial-results">need to know</a>.
Q1 Earnings: Toymaker Mattel reported first-quarter revenue of $827 million, beating analyst estimates of $786.01 million. The company reported a first-quarter adjusted loss of three cents per share, beating estimates for a loss of 10 cents per share, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 2% year-over-year, driven by a 3% increase in North America and a 1% increase in International. The company reported a first-quarter gross margin of 49.4%, up from 48% in the prior year&#8217;s quarter.
Mattel repurchased $160 million worth of shares in the quarter and ended the period with approximately $1.24 billion in cash and cash equivalents. The company said it was maintaining its $600 million share repurchase target for 2025. 
&#8220;This was a strong quarter for Mattel, with positive performance and continued operational excellence. Our brands are thriving, our products and experiences stand out in the marketplace, and our balance sheet gives us resilience and flexibility to execute our strategy,&#8221; said Ynon Kreiz, chairman and CEO of Mattel.
&#8220;As we navigate the current period of macro-economic volatility, we are adapting with speed, agility, and discipline. We expect not only to manage through this period but strengthen our competitive position.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/05/45209366/clorox-stock-drops-after-worse-than-expected-q3-results-heightened-macroeconomic-uncertainties-lowered-sales-ceo-says">Clorox Stock Drops After Worse-Than-Expected Q3 Results: &#8216;Heightened Macroeconomic Uncertainties&#8217; Lowered Sales, CEO says</a>
Mattel said it will take mitigating actions designed to fully offset the potential incremental cost impact of tariffs on future performance, including accelerating diversification of its supply chain, optimizing product sourcing and mix and taking pricing actions where necessary. 
The company also announced plans to accelerate cost savings and is increasing its 2025 savings target from $60 million to $80 million. 
Mattel said it will pause its full-year 2025 guidance, given the &#8220;volatile macro-economic environment and evolving U.S. tariff landscape.&#8221; The company noted that it will provide guidance again when it has &#8220;sufficient visibility.&#8221;
Mattel executives are discussing details from the quarter on a conference call that kicked off at 5 p.m. ET.
MAT Price Action: <a href="http://benzinga.com/quote/mat">Mattel shares</a> were down 2.47% in Monday&#8217;s after-hours session, trading at $15.80 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/rblfmr">rblfmr</a>/Shutterstock.

After-Hours Center

Mattel Beats Q1 Estimates, Pauses Guidance Due To Tariffs, Plans Actions To Mitigate Cost Impacts

Celanese Announces Engineered Materials Price Increases; Price Increases Are Associated With Heightened Costs Of Product Movement And Inventory Repositioning, Plant Operational Expenses, Changing Trade Regulations, And Raw Materials; Increases Will Be Effective On June 1, 2025

General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) announced today the pricing of three series of senior unsecured fixed rate notes for a total of $2.0 billion. These notes include $750.0 million of 5.350% notes due in 2028, $750.0 million of 5.625% notes due in 2030 and $500.0 million of 6.250% notes due in 2035. The offering is expected to settle on May 7, 2025.
GM intends to use the net proceeds from the sale of the notes for general corporate purposes, including to refinance a portion of the $1.25 billion outstanding of its 6.125% senior notes maturing on October 1, 2025, and fund a portion of the $1.8 billion five-year term loan it has agreed to make to Ultium Cells LLC, its joint venture with LG Energy Solution, to facilitate full voluntary prepayment of loans Ultium Cells LLC received under the U.S. Department of Energy's Advanced Technology Vehicles Manufacturing program.

Offerings

General Motors Announces The Pricing Of Three Series Of Senior Unsecured Fixed Rate Notes For A Total Of $2B

Citigroup analyst Stephen Trent maintains JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Neutral and raises the price target from $4.25 to $5.

Price Target

Analyst Ratings

JBLU

Citigroup Maintains Neutral on JetBlue Airways, Raises Price Target to $5

Cheetah Net Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 55.77 percent increase over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $479.80 thousand which beat the analyst consensus estimate of $100.00 thousand by 379.80 percent. This is a 524.46 percent increase over sales of $76.83 thousand the same period last year.

CTNT

Cheetah Net Supply Chain Q1 EPS $(0.23) Misses $(0.21) Estimate, Sales $479.80K Beat $100.00K Estimate

Diamondback Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NYSE">FANG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/05/g45206097/diamondback-energy-inc-announces-first-quarter-2025-financial-and-operating-results">from the report. </a>
The Details: Diamondback Energy reported adjusted earnings of $4.54 per share, which beat the analyst consensus estimate of $4.13. Quarterly revenue clocked in at $4.05 billion, beating the $3.73 billion consensus estimate.
Read Next:<a href="https://www.benzinga.com/news/earnings/25/05/45194998/saudi-arabias-oil-power-play-jolts-markets-can-diamondback-and-rivals-survive-the-squeeze?utm_source=articleShare">Saudi Arabia&#8217;s Oil Power Play Jolts Markets: Can Diamondback And Rivals Survive The Squeeze?</a>
For the first quarter, Diamondback Energy reported: 
<ul>
<li>Average oil production of 475.9 MBO/d (850.7 MBOE/d).</li>
<li>Net cash provided by operating activities of $2.4 billion; Operating Cash Flow Before Working Capital Changes of $2.5 billion.</li>
<li>Cash capital expenditures of $942 million.</li>
<li>Adjusted Free Cash Flow of $1.6 billion</li>
<li>Declared Q1 2025 base cash dividend of $1.00 per share payable on May&nbsp;22, 2025, implying a 2.9% annualized yield based on May&nbsp;2, 2025 closing share price of $136.81. </li>
</ul>
The company will host a conference call to discuss the results on Tuesday at 9 a.m. ET. 
Outlook: Diamondback Energy sees full-year 2025 oil production of 480 to 495 MBO/d (857-900 MBOE/d) and cash capital expenditures guidance of $3.4 billion to $3.8 billion.
FANG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Diamondback Energy stock was down 0.054% after-hours at $133.01 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/management/25/05/45180224/these-ev-makers-could-shine-if-musk-leaves-tesla?utm_source=articleShare">These EV Makers Could Shine If Musk Leaves Tesla</a></li>
</ul>
Image: Shutterstock

Commodities

FANG

Diamondback Energy Reports Better-Than-Expected Q1: Details

Bain Capital Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCSF#NYSE">BCSF</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.47 by 6.38 percent. This is a 5.66 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $66.84 million which missed the analyst consensus estimate of $71.00 million by 5.86 percent. This is a 10.28 percent decrease over sales of $74.50 million the same period last year.

BCSF

Bain Capital Specialty Q1 EPS $0.50 Beats $0.47 Estimate, Sales $66.84M Miss $71.00M Estimate

FDA lifts clinical hold enabling resumption of clinical trials
FDA has granted a Type A Meeting to discuss path forward for BLA
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.atarabio.com%2F&amp;esheet=54249346&amp;newsitemid=20250505744665&amp;lan=en-US&amp;anchor=Atara+Biotherapeutics%2C+Inc.&amp;index=1&amp;md5=1c32768a01374adbfe2795637b823f9c">Atara Biotherapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Atara's active Investigational New Drug (IND) applications for the EBVALLO&#x2122; (tabelecleucel) program.

ATRA

Atara Biotherapeutics Provides Regulatory Updates On EBVALLO; FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials; FDA Has Granted A Type A Meeting To Discuss Path Forward For BLA

Stock Split

RNAZ

TransCode Therapeutics Approved An Effective Time At 12:01 a.m. EST May 15, 2025, For Its 1-For-28 Reverse Stock Split

Citigroup analyst Kyle Menges maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and raises the price target from $12 to $14.

Citigroup Maintains Buy on CNH Industrial, Raises Price Target to $14

Citigroup analyst Kyle Menges maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Buy and raises the price target from $90 to $110.

AGCO

Citigroup Maintains Buy on AGCO, Raises Price Target to $110

Citigroup analyst Yigal Nochomovitz maintains Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Neutral and lowers the price target from $10 to $9.5.

Comments

Inseego

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL